Charles River and Purespring Therapeutics Announce Gene Therapy Manufacturing Collaboration
Plasmid CDMO alliance supports first gene therapy platform targeting kidney diseasesWILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announced a...
Source: pharmiweb.com